Kazia Therapeutics (KZIA) Non-Current Deffered Revenue (2016)
Kazia Therapeutics (KZIA) reported Non-Current Deffered Revenue of $613157.0 for Q4 2016, up 16.71% quarter-over-quarter from $525379.1 in Q2 2016.
Kazia Therapeutics (KZIA) Non-Current Deffered Revenue (2016) Analysis & Trends
Kazia Therapeutics has reported Non-Current Deffered Revenue for 1 years, with the latest figure at $613157.0 in Q4 2016.
- For the quarter ending Q4 2016, Non-Current Deffered Revenue changed N/A year-over-year to $613157.0; the trailing twelve-month figure through Dec 2016 stood at $613157.0 (changed N/A YoY), and the FY2016 full-year result was $512780.6, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q4 2016 stood at $613157.0, up from $525379.1 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $613157.0 in Q4 2016, with the low at $525379.1 in Q2 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kazia Therapeutics | 1.70 Bn | 1.70 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 613,156.97 |
| Jun 30, 2016 | 525,379.07 |